ストックスクリーナーアプリを入手
16.57
6.49%
1.01
アフターアワーズ：
16.60
0.03
+0.18%
Neogenomics Inc (NEO) 最新ニュース
NeoGenomics (NEO) Is Down 7.7% After DOJ Settlement On Legacy Agreements – Has The Bull Case Changed? - simplywall.st
NeoGenomics in focus: Earnings test new diagnostic momentum By Investing.com - Investing.com South Africa
NeoGenomics pays $10 million to settle kickback allegations after self-disclosing below-market deals - Peoples Gazette Nigeria
NEO Balance Sheet - TradingKey
NEO|Neogenomics Inc|Price:13.890|Chg%:-0.350 - TradingKey
NEOUSD (NEOUSD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NEO Income Statement - TradingKey
NEOUSD (NEOUSD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For - Yahoo! Finance Canada
NeoGenomics Laboratories to Pay $9.8 Million to Resolve FCA Allegations Relating to Below-Fair-Market-Value Consulting Services - ArentFox Schiff
Neogenomics Inc|Price:13.890|Chg%:-0.350 - TradingKey
NEO|Neogenomics Inc|Price:13.550|Chg%:+0.410 - TradingKey
NeoGenomics Inc. (NEO) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics Inc. (NEO) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics, Inc. Revenue Breakdown – SWB:NG9 - TradingView
NeoGenomics Inc. (NEO) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics Inc. (NEO) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics, Inc. (NEO) stock price, news, quote and history - Yahoo Finance UK
NEOGENOMICS INC : BENCHMARK RAISES TARGET PRICE TO $16 FROM $11 - Bitget
NEO Maintained by Benchmark -- Price Target Raised to $16.00 - GuruFocus
Benchmark Co. Maintains NeoGenomics(NEO.US) With Buy Rating, Raises Target Price to $16 - Moomoo
NeoGenomics Inc. (NEO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics Inc. (NG9) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics Inc. (NG9) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics Inc. (NG9) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics Resolves Federal Healthcare Compliance Probe with $9.8 Million DOJ Settlement - Kalkine Media
NeoGenomics, Inc. Files 8-K/A Amendment Disclosure for July 2026 – NASDAQ: NEO Company Details & Regulatory Update – Minichart - Minichart
Florida lab to pay $9.8 million to settle federal healthcare fraud allegations - Baltimore Sun
NeoGenomics Settles DOJ Investigation Related to Laboratory Collaboration Program - Moomoo
NeoGenomics, Inc. Files 8-K Report on July 20, 2026 – Key Corporate and Financial Disclosure Details - Minichart
NeoGenomics to Pay $9.8M to Resolve Allegations of False Claims Act Violation - Moomoo
NeoGenomics finalizes $9.81M DOJ settlement over voluntary OIG-HHS disclosure - TradingView
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS - Business Wire
NeoGenomics to Pay $9.8 Million to Resolve Allegations of False Claims Act Violation - marketscreener.com
(NEO) Volatility Zones as Tactical Triggers - Stock Traders Daily
Frontier tech research, news & data - MLQ.ai
PRPO vs. NEO: Which cancer diagnostics stock is the better buy? - MSN
NeoGenomics (NEO) Stock Looks Above Fair Value After A 134% Run - Yahoo Finance Singapore
Is NeoGenomics (NEO) Undervalued After Its FDA Approved PTEN Test Launch? - Yahoo Finance
NeoGenomics (NEO) Launches PTEN IHC CDx, Does The Valuation Still Look Full? - Sahm
NGMS stock holds its ground after Neogenomics revenue trends improve - Ad-hoc-news.de
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy? - The Globe and Mail
ETFs Investing in NeoGenomics, Inc. Stocks - TradingView
Bank of America Securities Reaffirms Their Hold Rating on NeoGenomics (NEO) - The Globe and Mail
Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift? - simplywall.st
NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $15.67, Implies 11% Upside - TradingView
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Raises Target Price to $16 - Moomoo
NeoGenomics Q1 2026 Earnings: Narrow Profit Beats Estimates Amid Market SkepticismRevenue Guidance Range - dars.gov.et
NeoGenomics Inc (NEO) Shares Fall 4.2% -- What GF Score of 72 Te - GuruFocus
NeoGenomics launches $275M convertible notes offering due 2032 - MSN
Press Release: NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026 - 富途牛牛
NeoGenomics (NEO) stock trades up, here is why - MSN
NeoGenomics (NEO) Stock Trades Up, Here Is Why - Yahoo Finance
NeoGenomics launches FDA-approved prostate cancer diagnostic test By Investing.com - Investing.com Nigeria
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer - BioSpace
NeoGenomics launches FDA-approved prostate cancer diagnostic test - Investing.com
NeoGenomics Inc focuses on diagnostics growth as investors watch long-term margins - Ad-hoc-news.de
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026 - BioSpace
0.30%
0.28%
大文字化:
|
ボリューム (24 時間):